As COVID Public Health Emergency Winds Down, US FDA Employs Flexibility For Rx EUA Transitions
Executive Summary
Biden administration sets May 11 as end date for public health emergency. CDER has said it will work with sponsors to help them gain approval of COVID therapeutics cleared under emergency use authorizations, but agency will likely not issue a formal transition framework.
You may also be interested in...
Many US COVID-19 Guidances Set To Sunset With Emergency Declaration
But some, including some related to inspections and master protocols, will remain in effect to allow for revisions or a transition out of the pandemic posture.
COVID-19 Vaccine Strain Updates Don’t Exactly Fit Flu Model
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.
Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.